Nice price and volume expansion. The technical indicator at stoxline website shows a strong buy with the $17.58 target price in six months.
Volume is due to their second offering. They need more money to fund their dead-end research and clinical trial. This company is a cash burner. Their pipelines will always be weak due to weak leadership and inadequate management.